Shareholder information
On 2 February 2026, AstraZeneca implemented its harmonised listing structure in London, Stockholm and New York. The way in which you hold AstraZeneca securities may change, please refer to the “Shareholder FAQs” section of our website for further details.
Shareholder FAQsHome / Investor relations / Shareholder information
The Board's aim is to strike a balance between the interest of the business, our financial creditors and our shareholders. Dividends will normally be paid twice a year, with a greater proportion paid as a second interm.
Upcoming events
Annual General Meeting and General Meeting information
2026
2025
General Meeting 3 November 2025
Annual General Meeting
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Tax information: Alexion
You can download a copy of Form 8937 prepared in relation to the Alexion transaction here. This form will be available on the AstraZeneca website until 31 December 2031.
Tax Information: Fusion
You can download a copy of the 2024 PFIC Annual Information Statement in relation to the Fusion transaction here. This document will be available on the AstraZeneca website until 31 December 2029.
-
Investor Relations contacts
For investor enquiries, please contact our team
-
Shareholder FAQs
Answers to frequently asked shareholder questions
-
Governance
We apply the principles of good corporate governance in the UK Corporate Governance Code and related guidance
